The Clinical Pharmacology of Metocurine: Dimethyltubocurarine Revisited

Publisher Website
Google Scholar
Abstract
The clinical pharmacology of metocurine (formerly dimethyltubocurarine) was studied in 55 patients. Evoked force of thumb adduction was measured at 0.15 Hz during nitrous oxide-morphine-thiopental anesthesia. The ED50 and ED95 for twitch inhibition were 0.13 and 0.28 mg/kg. The dose-response curve did not differ significantly from parallelism with curves for pancuronium and d-tubocurarine. Potency ratios were 0.25 and 1.8 vs. pancuronium and d-tubocurarine. The speed of onset and the duration of metocurine-induced block at high dosage employed for tracheal intubation did not differ significantly from the corresponding values obtained for approximately equipotent doses of pancuronium and d-tubocurarine. Metocurine, 0.3 mg/kg, produced 96.1% mean twitch depression within 4.8 .+-. 0.6 (SEM) [Standard Error of the Means] min. Recovery to 25% of the control twitch height took 82.4 .+-. 12.0 (SEM) min at this dose. Doses in the range 0.2-0.3 mg/kg are recommended for the production of abdominal relaxation during NO2-narcotic-thiopental anesthesia. Jaw relaxation was sufficient at 0.3 mg/kg for smooth tracheal intubation in 13 of 15 patients. Neostigmine antagonism of metocurine-induced block required dosage and timing similar to those of d-tubocurarine and pancuronium. Metocurine produced no significant change in heart rate or mean arterial pressure in doses as high as 0.3 mg/kg. At o.4 mg/kg, heart rate increased 18% and arterial pressure decreased 6.3%. These changes were statistically significant but generally not clinically important and reflect a short-lasting (5-10 min) response suggestive of histamine release, which occurred in 6 of 18 subjects who received this dose.